New training program aims to catch rare heart disease earlier

NCT ID NCT07338942

Ongoing Diagnosis Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study enrolls about 4,000 adults aged 60 and older with heart failure who are at high risk for ATTR amyloidosis, a rare disease that stiffens the heart. Doctors receive special training on how to spot and diagnose the condition using standard tests. The goal is to see if this training helps identify more cases early, so patients can get treatment sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure familial amyloid neuropathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTR-CM

Contacts and locations

Locations

Research Site

Beijing, 100029, China
Research Site

Beijing, 100034, China
Research Site

Beijing, 100037, China
Research Site

Beijing, 100142, China
Research Site

Beijing, 100191, China
Research Site

Changlexi, 710032, China
Research Site

Changsha, 410000, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410011, China
Research Site

Chengdu, 610041, China
Research Site

Chengdu, 610072, China
Research Site

Chongqing, 400016, China
Research Site

Chongqing, 400030, China
Research Site

Dalian, 116011, China
Research Site

Fuzhou, 350001, China
Research Site

Fuzhou, 350005, China
Research Site

Guangdong Province, 510060, China
Research Site

Guangzhou, 510100, China
Research Site

Guangzhou, 510515, China
Research Site

Guiyang, 550044, China
Research Site

Hangzhou, 310009, China
Research Site

Harbin, 150001, China
Research Site

Hefei, 230001, China
Research Site

Hefei, 230022, China
Research Site

Jinan, 250012, China
Research Site

Jinan, 250021, China
Research Site

Nanchang, 330006, China
Research Site

Nanjing, 210006, China
Research Site

Nanjing, 210029, China
Research Site

Nanning, 530000, China
Research Site

Qingdao, 266003, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200040, China
Research Site

Shanghai, 200080, China
Research Site

Shanghai, China
Research Site

Shenyang, 110001, China
Research Site

Shijiazhuang, 050001, China
Research Site

Shijiazhuang, 50051, China
Research Site

Suzhou, 215006, China
Research Site

Taiyuan, 030001, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430030, China
Research Site

Wuhan, 430060, China
Research Site

Wuhan, 430071, China
Research Site

Wuhan, CN-430022, China
Research Site

Xi'an, 710061, China
Research Site

Xiamen, 361003, China
Research Site

Zhengzhou, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.